<DOC>
	<DOCNO>NCT00369317</DOCNO>
	<brief_summary>This phase III trial study well combination chemotherapy work treat young patient Down syndrome acute myeloid leukemia myelodysplastic syndrome . Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Young Patients With Down Syndrome Acute Myeloid Leukemia Myelodysplastic Syndromes</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine event-free survival ( EFS ) overall survival rate pediatric patient Down syndrome ( DS ) acute myeloid leukemia AML myelodysplastic syndrome MDS treat induction therapy comprise cytarabine , daunorubicin hydrochloride , thioguanine , asparaginase follow intensification therapy comprise cytarabine etoposide . II . Determine EFS rate patient increase intensified course cytarabine therapy induction therapy , compare EFS rate patient protocol COG-A2971 . III . Determine number intrathecal chemotherapy treatment reduce patient . IV . Determine total cumulative anthracycline dose reduce patient . SECONDARY OBJECTIVES : I . Determine type degree treatment-related toxicity patient . II . Determine prevalence leukemia phenotype globin transcription factor 1 ( GATA1 ) mutation DS patient &lt; 4 year age diagnosis . III . Determine relationship GATA1 mutation leukemia phenotype EFS rate DS patient &lt; 4 year age diagnosis . IV . Determine relationship minimal residual disease monitor flow cytometry remission status completion therapy base bone marrow morphology . V. Examine parameter vitro drug sensitivity vivo Ara-C pharmacokinetics . VI . Examine gene expression profile microarrays relationship leukemia phenotype outcome . VII . Examine relationship functional polymorphism phase I phase II detoxification gene DNA repair pathway may modify susceptibility leukemia outcome therapy DS child . VIII . Assess effect karyotypic abnormality survival . IX . Establish DS leukemia cell bank future biological study . OUTLINE : This nonrandomized , multicenter study . INDUCTION THERAPY : Patients undergo 4 course induction therapy . Each course 28 day . COURSE I : Patients receive intrathecal ( IT ) cytarabine day 1* cytarabine IV continuously 96 hour , daunorubicin hydrochloride IV continuously 96 hour , oral thioguanine twice daily day 1-4 . NOTE : *Patients Central Nervous System ( CNS ) disease receive cytarabine IT twice weekly 6 dos ; patient persistent CNS leukemia 6 dose IT cytarabine remove study . COURSE II : Patients receive high-dose cytarabine IV 3 hour twice daily day 1 , 2 , 8 , 9 asparaginase intramuscularly ( IM ) day 2 9 . COURSE III : Patients receive treatment course 1 . COURSE IV : Patients receive cytarabine IV , daunorubicin hydrochloride IV , oral thioguanine course 1 . Induction therapy continue absence disease progression unacceptable toxicity . Patients partial response , relapse , refractory disease completion course 4 take study . Patients achieve complete response proceed intensification therapy . INTENSIFICATION THERAPY : Patients receive cytarabine IV continuously 168 hour day 1-7 etoposide IV 1 hour day 1-3 . Treatment repeat every 28 day 2 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically 5 year annually thereafter .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Down Syndrome</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Hypereosinophilic Syndrome</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Eosinophilic , Acute</mesh_term>
	<mesh_term>Leukemia , Basophilic , Acute</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<criteria>Diagnosis DS DS mosaicism karyotype chromosomal analysis Diagnosis myelodysplastic syndrome ( MDS ) &lt; 30 % blast acute myeloid leukemia ( AML ) Newly diagnose disease Patients history transient myeloproliferative disorder ( TMD ) eligible provide patient diagnose AML MDS &gt; 90 day age AND meet either follow criterion : At least 30 % blast bone marrow regardless time since resolution TMD More 8 week since resolution TMD ≥ 5 % blast bone marrow Immunophenotype require study entry No promyelocytic leukemia Shortening fraction ≥ 27 % echocardiogram OR ejection fraction ≥ 50 % radionuclide angiogram Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT &lt; 2.5 time ULN Creatinine adjust accord age follow : No great 0.4 mg/dL ( ≤ 5 month ) No great 0.5 mg/dL ( 6 month 11 month ) No great 0.6 mg/dL ( 1 year23 month ) No great 0.8 mg/dL ( 2 years5 year ) No great 1.0 mg/dL ( 6 years9 year ) No great 1.2 mg/dL ( 10 years12 year ) No great 1.4 mg/dL ( 13 year [ female ] ) No great 1.5 mg/dL ( 13 year 15 year [ male ] ) No great 1.7 mg/dL ( 16 year [ male ] ) Creatinine clearance radioisotope glomerular filtration rate least 70 mL/min No evidence dyspnea rest No exercise intolerance Pulse oximetry &gt; 94 % No prior chemotherapy , radiotherapy , antileukemic therapy Intrathecal cytarabine therapy give diagnosis allow Prior therapy TMD allow</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>4 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>